Download Full eBooks in PDF
Overcoming Breast Cancer Therapy Resistance Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Overcoming Breast Cancer Therapy Resistance book. This book definitely worth reading, it is an incredibly well-written.
Author : Zodwa Dlamini
Publisher : Springer Nature
Page : 390 pages
File Size : 53,7 Mb
Release : 2024-06-30
Category : Electronic
ISBN : 9783031528606
Author : Zodwa Dlamini
Publisher : Springer
Page : 0 pages
File Size : 47,9 Mb
Release : 2024-05-08
Category : Medical
ISBN : 303152859X
This book addresses the pressing problem of drug resistance in the treatment of breast cancer. It provides a comprehensive understanding of the complex mechanisms underlying drug resistance and presents the latest advances in therapeutic approaches to overcome this enormous challenge. The book begins with an introduction to the biology of breast cancer, treatment modalities and the mechanisms of drug resistance. This includes the principles of drug resistance in targeted, immune-, endocrine and chemotherapy. In the following sections, the authors present innovative strategies to overcome drug resistance and new research directions, among others the role of the microbiome in drug resistance, molecular profiling of patients for personalized medical care, and new drug delivery systems. Finally, the book concludes with a discussion of the differences in the prevalence and treatment success of breast cancer between high- and low-income countries. This book is an informative resource for students, researchers, and clinicians in the field of breast cancer research and oncology in general.
Author : Zhi-Gang Zhuang,Helena Chang,Chunyan Dong
Publisher : Frontiers Media SA
Page : 183 pages
File Size : 40,7 Mb
Release : 2023-12-29
Category : Medical
ISBN : 9782832541883
Author : Gw Sledge,George W. Sledge (Jr.)
Publisher : Clinical Pub
Page : 0 pages
File Size : 45,8 Mb
Release : 2012-06
Category : Breast
ISBN : 1846920663
This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
Author : Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
Publisher : Springer
Page : 320 pages
File Size : 43,8 Mb
Release : 2019-07-15
Category : Medical
ISBN : 9783030214777
Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.
Author : Dihua Yu,Mien-Chie Hung
Publisher : Springer
Page : 0 pages
File Size : 43,8 Mb
Release : 2010-11-29
Category : Medical
ISBN : 1441925422
In Breast Cancer Chemosensitivity, a group of world leading experts review critical aspects of resistance to systemic therapy in breast cancer patients. Beginning with a clinical overview of the problem, the book then focuses on the latest findings of molecular mechanisms of drug resistance. Coverage provides an example of using novel approaches for chemosensitization of breast cancer cells that gives readers an idea about the future direction in breast cancer treatment. It allows those who are interested in breast cancer therapy to get a jump-start on critical issues in breast cancer therapeutic resistance.
Author : Maria Rosaria De Miglio,Anca Maria Cimpean,Dayanidhi Raman
Publisher : Frontiers Media SA
Page : 178 pages
File Size : 52,7 Mb
Release : 2023-02-03
Category : Medical
ISBN : 9782832513651
Author : Yan Cheng,Jin-Ming Yang,Ceshi Chen,Yi Zhang
Publisher : Frontiers Media SA
Page : 198 pages
File Size : 42,8 Mb
Release : 2024-01-11
Category : Medical
ISBN : 9782832541845
Basic scientific background Breast cancer is one of the most common cancer and the most frequent cause of cancer death among women worldwide. Currently, subtyping breast cancers into hormone receptor (HR) positive, human epidermal growth factor receptor-2 overexpressing (HER2+), and triple negative breast cancer (TNBC) is the basis of diagnosing and treating this disease. The main treatment strategies for breast cancer include surgery, endocrine therapy, molecular targeted therapy, chemotherapy, radiotherapy, immunotherapy and gene therapy. However, resistance of breast cancer cells to chemotherapeutic agents, molecular targeted therapies and immunotherapy may occur either intrinsically or de nova, and is often ultimately responsible for treatment failure. Therefore, drug resistance poses a major challenge to breast cancer treatment. Current developments: Drug resistance in breast cancer is a complex clinical condition originating from a wide range of molecular alterations. The development of endocrine therapy resistance is believed to be associated with many cellular changes, such as ESR1 gene mutations, bypassing estrogen signaling pathway and altered tamoxifen metabolism. Meanwhile, changes in immune response, alternation of drug-binding property and downstream pathways are involved in the mechanisms of drug resistance in HER2+ breast cancer. In addition, resistance to chemotherapeutic agents predominantly arises from increased drug efflux and cross resistance. Current studies suggest that treatment strategies and therapeutics have to be designed specifically to each patient in different clinical situations. The use of modern genomic, proteomic and functional analytical techniques has contributed to identify novel genes and signaling networks involved in breast cancer drug resistance. Moreover, the use of high-throughput techniques in combination with bioinformatics and systems biology approaches has aided the interrogation of clinical samples and allowed the identification of molecular signatures and genotypes that predict responses to certain drugs. Despite much progress has been made in the field of breast cancer drug resistance, such as combination therapy and drug-loaded nanoparticles, the complexity and variability of drug resistance mechanism still inevitably lead to the continuous occurrence of drug resistance. Therefore, with the increasing amounts of anti-breast cancer agents, there are now unprecedented opportunities to understand and overcome drug resistance through further research into mechanisms and corresponding strategies, which will help achieve lasting disease control and bring survival benefits to patients with advanced cancer. Papers of interest: The current Research Topic of Frontiers in Pharmacology focuses on publishing Original Research, Review articles and Case Reports focusing on (a) elucidating mechanisms of drug resistance in breast cancer, target mutations, tumor microenvironment, undiscovered genes and signaling pathways; (b) promising drug delivery systems that can enhance the sensitivity of anti- breast cancer agents to various tumors; (c) strategies that can improve patient care during bio-chemotherapeutic treatments; (d) small molecule compounds that are effective against drug-resistant breast tumors (e) biomarkers of chemotherapy resistance in breast cancer patients and (f) in vitro and in vivo models. Guidelines for article of submission: - Authors must stick to the set guidelines for ethical practices by the Frontiers journals. - The main content of the article must have certain innovation and research significance. - The authors should describe the construction method of drug-resistant cell lines when using them for experiments in the article.
Author : Monica Castiglione,Martine J. Piccart
Publisher : Springer Science & Business Media
Page : 483 pages
File Size : 52,6 Mb
Release : 2009-07-11
Category : Medical
ISBN : 9780387751153
Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.
Author : Jenifer R. Prosperi
Publisher : Springer
Page : 184 pages
File Size : 51,8 Mb
Release : 2017-12-04
Category : Medical
ISBN : 9783319701424
We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.
Author : Alexey Larionov
Publisher : Springer
Page : 288 pages
File Size : 53,5 Mb
Release : 2015-04-25
Category : Medical
ISBN : 9783319179728
Aromatase Inhibitors (AIs) treat postmenopausal estrogen receptor positive tumours, which constitute the majority of breast cancer patients. This comprehensive volume brings together the current knowledge from different relevant areas, including molecular mechanisms and translational aspects of drug resistance in AIs. Topics covered include research, experimental , and clinical data specifically focused on AI resistance in breast cancer. The volume will include three sections. The first section covers general knowledge about aromatase inhibitors, including regulation of aromatase genes, and structure and function of aromatase protein. The second section provides the detailed mechanisms of resistance to AIs, while the third section explores prediction of resistance and potential strategies to overcome resistance. Breast cancer is the most common female cancer and AIs significantly improve treatments outcomes compatibly to previously used endocrine treatments. However 10-15% of post-operative patients develop a relapse during adjuvant treatment with AIs; about 25-50% of the patients do not respond to AIs in neo-adjuvant or metastatic setting, and the majority of metastatic patients who initially respond develop resistance within 3 years. There is an important need to understand these mechanisms of resistance in order to develop methods of preventing or overcoming the resistance to AIs, which will ensure a more successful outcome in treating breast cancer.
Author : Erwei Song,Hai Hu
Publisher : Springer
Page : 0 pages
File Size : 45,7 Mb
Release : 2018-12-11
Category : Medical
ISBN : 9811355509
This book offers a comprehensive introduction to translational efforts in breast cancer, addressing the latest approaches to precision medicine based on the current state of understanding of breast cancer. With the latest developments in breast cancer research, our understanding of the genomic changes and the oncogenic signaling cascade of breast cancer has made considerable strides. Further, the immuno-environment has been demonstrated as the barrier to clinical cancer. In addition, major advances in cancer biology, immunology, genomics and metabolism have broken new ground for designing therapeutic approaches and selecting appropriate treatments on the basis of more precise information on the individual patient. As a result of these two trends, a clearer picture of the molecular landscape of breast cancers has facilitated the development of diagnostic, prognostic and predictive biomarkers for clinical oncology. All these aspects are addressed in this volume, which offers a comprehensive resource for researchers, graduate students and oncologists in cancer research.
Author : Anonim
Publisher : Academic Press
Page : 390 pages
File Size : 47,9 Mb
Release : 2021-08-11
Category : Science
ISBN : 9780128243008
Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers
Author : Xiaoting Zhang
Publisher : Humana Press
Page : 432 pages
File Size : 44,6 Mb
Release : 2019-11-08
Category : Electronic
ISBN : 3030075931
The discovery of ER by Dr. Elwood Jensen exactly 60 years ago has not only led to the birth of a whole new vital nuclear receptor research field but also made a rapid, direct and lasting impact on the treatment and prevention of breast cancer. Since that landmark discovery, tremendous progress has been made in our understanding of the molecular functions of ER and development of targeted therapies against ER pathways for breast cancer treatment. However, there is currently no book available addressing these discoveries and recent advancement in a historical and systematic fashion. This book is intended to provide comprehensive, most up-to-date information on the history and recent advancement of ER and breast cancer by world renowned leaders in the field. These chapters include the history of the discovery of ER; physiological and pathological roles of ER; recent discovery of ER cistrome, transcriptome and its regulation of noncoding RNAs such as microRNAs and enhancer RNAs in breast cancer; development and clinical practices of the first targeted therapy Tamoxifen and other antiestrogens for breast cancer treatment; structural basis of ER and antiestrogen actions; molecular insights into endocrine resistance; the role of ER mutants, ER-beta and environmental estrogens in breast cancer; and emerging state-of-the-art therapeutic approaches currently in development to overcome treatment resistance and future perspectives. The book will provide undergraduate and graduate students, basic scientists and clinical cancer researchers, residents, fellows, as well as clinicians, oncology educators and the general public a thorough and authoritative review of these exciting topics.
Author : William R. Miller,James N. Ingle
Publisher : CRC Press
Page : 395 pages
File Size : 45,9 Mb
Release : 2002-03-08
Category : Medical
ISBN : 9780203909836
This reference evaluates and describes the latest strategies for hormone suppression and blockade in the management of early and advanced stage breast cancer and explores the effects of tamoxifen, selective estrogen receptor modulators (SERMs), aromatase inhibitors, and their combination on both breast cancers and normal tissues. Endocrine T
